GastroPanel® Quick Test NT nominated for best new clinical diagnostic product in the Scientists’ Choice Awards

June 26, 2024

BIOHIT OYJ is proud to announce that its GastroPanel Quick Test NT has been nominated as the best new clinical diagnostic product in the prestigious SelectScience® Scientists’ Choice Awards. This nomination celebrates how this breakthrough diagnostic test is transforming gastroscopy workflows by swiftly triaging patients at the point of care.

GastroPanel Quick Test NT from BIOHIT is a rapid and quantitative immunochromatographic test for the detection of Helicobacter pylori (H. pylori) infection and atrophic gastritis in a clinic or point-of-care setting before referral to gastroscopy. This revolutionary test identifies high risk patients in just 15 minutes and includes an automatic reader to interpret results, enhancing the accuracy and efficiency of triaging. This helps to reduce costs associated with unnecessary endoscopy appointments, while speeding up the referral of patients who need further investigations.

Jussi Hahtela, CEO of BIOHIT OYJ, commented: “We are honoured that GastroPanel Quick Test NT has been nominated for the Scientists’ Choice Awards. This recognition reflects the hard work and dedication that went into developing the novel test, and highlights how this innovation is solving real-world challenges in atrophic gastritis screening, enhancing patient care and streamlining diagnostic processes.”

The Scientists’ Choice Awards celebrate the best scientific innovations as chosen by the global scientific community. Voting is open until the 16th of July 2024, and winners will be announced shortly after.

Vote now.

Click here for more information about GastroPanel Quick Test NT visit.


About BIOHIT HealthCare

BIOHIT HealthCare is a Finnish biotech company, headquartered in Helsinki, that specialises in the development, manufacture and distribution of kits and assays for the screening, diagnosis and monitoring of digestive diseases. Its core disease focus areas include stomach health and dyspepsia, reflux and acid dysregulation, Inflammatory Bowel Disease (IBD), functional gastrointestinal disorders (FGID), Irritable bowel syndrome (IBS), and gut microbiota dysbiosis. Innovating for Health www.biohithealthcare.co.uk

Recent Posts

The future of point-of-care testing in the healthcare landscape

January 23, 2025

Elevating gastrointestinal diagnostics with the ULTRA-FAST UFT300 Helicobacter pylori Quick Test

December 18, 2024

Why proton pump inhibitors aren’t always the answer for silent reflux

November 7, 2024

Is there a link between atrophic gastritis and osteoporosis?

October 15, 2024